Pfizer (PFE) Other Non-Current Assets (2009 - 2026)

Pfizer (PFE) has reported Other Non-Current Assets for 18 consecutive years, with $9.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets rose 5.12% year-over-year to $9.9 billion in Q2 2026; TTM through Jun 2026 was $9.9 billion, a 5.12% increase from a year earlier, with the FY2025 full-year figure at $9.6 billion, down 1.89% from the prior year.
• Other Non-Current Assets was $9.9 billion for Q2 2026 at Pfizer, up from $9.8 billion in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $13.2 billion in Q4 2022 and troughed at $7.7 billion in Q3 2022.
• A 5-year average of $10.5 billion and a median of $9.9 billion in 2025 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 71.42% in 2022 and dropped 21.28% in 2024, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $13.2 billion in 2022, then dropped by 5.26% to $12.5 billion in 2023, then declined by 21.28% to $9.8 billion in 2024, then declined by 1.89% to $9.6 billion in 2025, then increased by 3.2% to $9.9 billion in 2026.
• The last three Other Non-Current Assets figures came in at $9.9 billion (Q2 2026), $9.8 billion (Q1 2026), and $9.6 billion (Q4 2025), per Business Quant data.